Royal Bank of Canada’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $487M | Sell |
980,259
-131,612
| -12% | -$58.3M | 0.07% | 234 |
|
|
2026
Q1 | $496M | Sell |
1,111,871
-82,641
| -7% | -$38.5M | 0.09% | 218 |
|
|
2025
Q4 | $542M | Buy |
1,194,512
+803
| +0.1% | +$346K | 0.09% | 203 |
|
|
2025
Q3 | $468M | Sell |
1,193,709
-190,659
| -14% | -$79.7M | 0.08% | 228 |
|
|
2025
Q2 | $616M | Buy |
1,384,368
+175,700
| +15% | +$81M | 0.11% | 169 |
|
|
2025
Q1 | $586M | Sell |
1,208,668
-242,291
| -17% | -$113M | 0.12% | 156 |
|
|
2024
Q4 | $584M | Sell |
1,450,959
-116,677
| -7% | -$54.1M | 0.12% | 154 |
|
|
2024
Q3 | $729M | Sell |
1,567,636
-113,964
| -7% | -$54.7M | 0.15% | 126 |
|
|
2024
Q2 | $788M | Buy |
1,681,600
+170,396
| +11% | +$74M | 0.18% | 103 |
|
|
2024
Q1 | $632M | Buy |
1,511,204
+56,732
| +4% | +$24M | 0.14% | 131 |
|
|
2023
Q4 | $592M | Buy |
1,454,472
+224,276
| +18% | +$82.9M | 0.14% | 144 |
|
|
2023
Q3 | $428M | Buy |
1,230,196
+12,630
| +1% | +$4.42M | 0.12% | 166 |
|
|
2023
Q2 | $428M | Buy |
1,217,566
+91,890
| +8% | +$31M | 0.11% | 168 |
|
|
2023
Q1 | $355M | Buy |
1,125,676
+165,244
| +17% | +$49.6M | 0.1% | 179 |
|
|
2022
Q4 | $277M | Buy |
960,432
+37,192
| +4% | +$11.3M | 0.08% | 215 |
|
|
2022
Q3 | $267M | Buy |
923,240
+38,005
| +4% | +$10.9M | 0.08% | 206 |
|
|
2022
Q2 | $249M | Buy |
885,235
+45,140
| +5% | +$12.1M | 0.07% | 231 |
|
|
2022
Q1 | $219M | Buy |
840,095
+136,396
| +19% | +$32.4M | 0.05% | 291 |
|
|
2021
Q4 | $155M | Sell |
703,699
-76,891
| -10% | -$15M | 0.04% | 393 |
|
|
2021
Q3 | $142M | Sell |
780,590
-291,551
| -27% | -$56.9M | 0.04% | 387 |
|
|
2021
Q2 | $216M | Buy |
1,072,141
+230,563
| +27% | +$48.2M | 0.06% | 283 |
|
|
2021
Q1 | $181M | Sell |
841,578
-35,371
| -4% | -$7.77M | 0.05% | 306 |
|
|
2020
Q4 | $207M | Buy |
876,949
+147,020
| +20% | +$33.7M | 0.06% | 274 |
|
|
2020
Q3 | $199M | Buy |
729,929
+146,551
| +25% | +$40.4M | 0.07% | 239 |
|
|
2020
Q2 | $169M | Buy |
583,378
+50,299
| +9% | +$13.6M | 0.07% | 240 |
|
|
2020
Q1 | $127M | Sell |
533,079
-113,549
| -18% | -$26M | 0.06% | 252 |
|
|
2019
Q4 | $142M | Buy |
646,628
+36,459
| +6% | +$7.38M | 0.05% | 310 |
|
|
2019
Q3 | $103M | Buy |
610,169
+93,736
| +18% | +$16.6M | 0.04% | 363 |
|
|
2019
Q2 | $94.7M | Buy |
516,433
+4,635
| +0.9% | +$810K | 0.04% | 369 |
|
|
2019
Q1 | $94.1M | Sell |
511,798
-121,747
| -19% | -$22.5M | 0.04% | 357 |
|
|
2018
Q4 | $105M | Buy |
633,545
+65,058
| +11% | +$11.3M | 0.05% | 325 |
|
|
2018
Q3 | $109M | Buy |
568,487
+71,705
| +14% | +$12.8M | 0.05% | 334 |
|
|
2018
Q2 | $84.4M | Sell |
496,782
-70,569
| -12% | -$10.9M | 0.04% | 377 |
|
|
2018
Q1 | $92.5M | Buy |
567,351
+232,183
| +69% | +$37.9M | 0.04% | 364 |
|
|
2017
Q4 | $50.2M | Buy |
335,168
+171,670
| +105% | +$25.4M | 0.02% | 601 |
|
|
2017
Q3 | $24.9M | Buy |
163,498
+21,527
| +15% | +$3.24M | 0.01% | 960 |
|
|
2017
Q2 | $18.3M | Buy |
141,971
+57,178
| +67% | +$6.88M | 0.01% | 1106 |
|
|
2017
Q1 | $9.27M | Sell |
84,793
-30,920
| -27% | -$2.72M | 0.01% | 1532 |
|
|
2016
Q4 | $8.53M | Sell |
115,713
-44,510
| -28% | -$3.62M | ﹤0.01% | 1613 |
|
|
2016
Q3 | $14M | Buy |
160,223
+28,630
| +22% | +$2.71M | 0.01% | 1235 |
|
|
2016
Q2 | $11.3M | Buy |
131,593
+7,116
| +6% | +$615K | 0.01% | 1373 |
|
|
2016
Q1 | $9.89M | Buy |
124,477
+1,218
| +1% | +$110K | 0.01% | 1386 |
|
|
2015
Q4 | $15.5M | Buy |
123,259
+27,185
| +28% | +$3.28M | 0.01% | 1138 |
|
|
2015
Q3 | $10M | Sell |
96,074
-37,038
| -28% | -$4.76M | 0.01% | 1151 |
|
|
2015
Q2 | $16.4M | Buy |
133,112
+28,426
| +27% | +$3.58M | 0.01% | 938 |
|
|
2015
Q1 | $12.3M | Sell |
104,686
-71,574
| -41% | -$8.58M | 0.01% | 1089 |
|
|
2014
Q4 | $20.9M | Sell |
176,260
-215,310
| -55% | -$24.2M | 0.01% | 831 |
|
|
2014
Q3 | $44M | Buy |
391,570
+258,763
| +195% | +$24.6M | 0.03% | 423 |
|
|
2014
Q2 | $12.6M | Sell |
132,807
-48,381
| -27% | -$3.39M | 0.01% | 1079 |
|
|
2014
Q1 | $12.8M | Sell |
181,188
-73,583
| -29% | -$5.83M | 0.01% | 1009 |
|
|
2013
Q4 | $18.9M | Buy |
254,771
+48,655
| +24% | +$3.39M | 0.01% | 828 |
|
|
2013
Q3 | $15.6M | Buy |
206,116
+66,316
| +47% | +$5.28M | 0.01% | 874 |
|
|
2013
Q2 | $11.2M | Buy |
+139,800
| New | +$10.3M | 0.01% | 982 |
|
Other funds holding VRTX
Royal Bank of Canada's VRTX Position: Q2 2026 in Review
Royal Bank of Canada reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, selling an estimated $58.3M and leaving 980,259 shares worth $487M. The position accounts for 0.07% of the portfolio, ranked #234.
Royal Bank of Canada first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $788M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Royal Bank of Canada held 980,259 shares of Vertex Pharmaceuticals worth $487M as of Q2 2026.
- Royal Bank of Canada sold 131,612 Vertex Pharmaceuticals shares in Q2 2026, an estimated $58.3M.
- Vertex Pharmaceuticals made up 0.07% of Royal Bank of Canada's portfolio in Q2 2026, its #234 holding.
- Royal Bank of Canada first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Royal Bank of Canada's Vertex Pharmaceuticals position peaked at $788M in Q2 2024.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.